Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: J Immunol. 2008 Nov 15;181(10):7263–7272. doi: 10.4049/jimmunol.181.10.7263

Figure 5.

Figure 5

A Smad-dependent pathway is required for TGF-β to suppress Kit re-expression. Skin mast cells were incubated with SCF (100 ng/ml) ± SB431542 (10 μM) for 2 h before the addition of TGF-β. A, Surface expression of Kit at 48 h by flow cytometry. SCF alone (green) and SCF with TGF-β (blue), SB431542 (purple, right), and SB431542 + TGF-β (purple, left). Unlabeled cells (red) and an isotype control (black) are also shown. One representative experiment of three is shown. SB431542 had no effect on Kit re-expression after SCF in the absence of TGF-β (data not shown). B, Smad3 and p-Smad1/3 protein. Smad3 and p-Smad1/3 were detected 30 min after TGF-β treatment by Western blotting. β-Actin was used as housekeeping control. One representative experiment of three independent experiments with similar results is shown.